The 2022 Endpoints 11 is coming. Do you know a biotech that should be on the list? – Endpoints News

It’s time for some fun.

Over the past 20 years or so, I’ve made it my mission to hunt down some of the most promising private biotechs in the industry to feature in an annual report I now call the Endpoints 11. And we’re back on track for the next big round of awards.

Every now and then I’m asked what the basic criteria are for inclusion. It’s simple. If you’re out to do big things in drug development, break new ground, go to that proverbial next level with an outstanding team, promising science and marquee backers – or promise to make a colossal noise if you fail – then you should make the short list.

Premium Endpoints

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.


Leave a Reply

Your email address will not be published.